Surveyor Capital key facts
- Surveyor Capital is a hedge fund based in Chicago, Illinois with 20 tracked portfolio companies.
- Notable positions include Kailera Therapeutics (NAS: KLRA), Enveda, 35Pharma.
- PrivateMarketView records 1 deal participation by Surveyor Capital.
- The team roster lists 2 people.
About Surveyor Capital
Founded in 2008, Surveyor Capital is a hedge fund manager based in Chicago, Illinois. The firm employs even-driven, fundamental equity long/short and sector-focused investment strategies.
Investment activity
Surveyor Capital joined 1 recorded round in the last two years. 1 round landed in the last 90 days. Most recently: Enveda (Series E, Sep 2026).
Surveyor Capital portfolio at a glance
20 portfolio companies are on record for Surveyor Capital, including Kailera Therapeutics (NAS: KLRA), Enveda and 35Pharma. The book leans Drug Discovery (4) and Discovery Tools (Healthcare) (2).
20 of the 20 carry a recorded valuation.
Surveyor Capital team
2 people are on record at Surveyor Capital. Senior names include Daniel Krizek (Portfolio Manager) and Michael Wax (Portfolio Manager). 2 of them have a verified direct contact on file.
Is this your firm? Sign in with your work email to keep it current, or tell us what's wrong.
- ·The top 10 names in the book — of 20 recorded positions
- ·Watchlist + alerts for Surveyor Capital's activity
Portfolio
20 companies · priced for members| Company | Industry | Valuation | First invested | Role |
|---|---|---|---|---|
| Kailera Therapeutics (NAS: KLRA) | — | ▮ | ▮ | ▮ |
| Enveda | — | ▮ | ▮ | ▮ |
| 35Pharma | — | ▮ | ▮ | ▮ |
+ 17 more companies · all 20, priced and dated or a free account shows the top 10 names — no card Membership and data by Private Market View | ||||
Surveyor Capital recent deals
1 recordedMembership and data by Private Market View
Partners, principals, and the people who answer a pitch. Pro members reveal contacts with credits.
Frequently asked about Surveyor Capital
- What companies does Surveyor Capital invest in?
- Surveyor Capital has 20 recorded portfolio companies, including Kailera Therapeutics (NAS: KLRA), Enveda, 35Pharma.